Table 2.
Clinical characteristics of patients, categorized according to body mass index classes
| BMI class | <18.5 kg/m2 n = 13 | 18.5–24.9 kg/m2 n = 134 | 25–29.9 kg/m2 n = 101 | ≥30 kg/m2 n = 47 |
|---|---|---|---|---|
| Age | 54 [39–68] | 57 [45–66] | 59 [52–68] | 60 [50–70] |
| Male gender | 60% | 83% | 88% | 79% |
| Diabetes | 10% | 27% | 34% | 38% |
| Hypertension | 40% | 58% | 63% | 70% |
| Ischaemic CMP | 50% | 46% | 51% | 47% |
| De novo HF | 70% | 44% | 51% | 47% |
| ACE‐I or ARB | 100% | 98% | 96% | 100% |
| Beta blockers | 100% | 90% | 86% | 94% |
| MRA | 50% | 54% | 49% | 55% |
| CRT | 20% | 15% | 12% | 13% |
| Heart rate (bpm)* | 80 [72–92] | 73 [65–88] | 73 [63–87] | 80 [70–97] |
| % change in BSA | 0.4 [0–0.9] | 0.1 [0–0.2] | 0 | 0 |
| % change in BMI | 0.8 [−0.2 to 12] | 0.1 [−0.1 to 0.2] | 0.2 [−0.1 to 0.3] | 0 [−0.1 to 0.1] |
| LVEDDi (mm/m2) | 36 [36–43] | 36 [34–39] | 34 [31–37] | 32 [30–34] |
| LVEDVi (mL/m2) | 130 [93–157] | 121 [99–149] | 113 [95–131] | 111 [92–134] |
| % change in LVEDDi* | 1.4 [−4.3 to 8.8] | −1.2 [−7.2 to 4.5] | −1.9 [−11.9 to 4.0] | −3.8 [−12.7 to 2.9] |
| LVEF (%) | 31 [20–40] | 30 [25–35] | 30 [25–35] | 30 [25–37] |
| Change in LVEF (%) | 0 [−10 to 5] | 0 [−5 to 10] | 2 [−1 to 6] | 3 [−3 to 8] |
| LVRR** | 0% | 10% | 26% | 30% |
ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BSA, body surface area; CMP, cardiomyopathy; CRT, cardiac resynchronization therapy; HF, heart failure; LVEDDi, left ventricular end‐diastolic diameter per m2; LVEDVi, left ventricular end‐diastolic volume per m2; LVEF, left ventricular ejection fraction; LVRR, left ventricular reverse remodelling; MRA, mineraloreceptor antagonists.
*
P < 0.05 between BMI classes.
**
P < 0.01 between BMI classes.